Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung

Citer cette référence
VIEIRA, Thibault, ANTOINE, Martine, RUPPERT, Anne-Marie, FALLET, Vincent, DURUISSEAUX, Michael, GIROUX LEPRIEUR, Etienne, POULOT, Virginie, RABBE, Nathalie, SCLICK, Laurene, BEAU-FALLER, Michele, LACAVE, Roger, LAVOLE, Armelle, CADRANEL, Jacques et WISLEZ, Marie, 2014. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer. 2014. Vol. 85, n° 2pp. 276-281. DOI 10.1016/j.lungcan.2014.06.004.
Pas de texte intégral
Auteurs Thibault Vieira
Martine Antoine
Anne-Marie Ruppert
Vincent Fallet
Michael Duruisseaux
Etienne Giroux Leprieur
Virginie Poulot
Nathalie Rabbe
Laurene Sclick
Michele Beau-Faller
Roger Lacave
Armelle Lavole
Jacques Cadranel
Marie Wislez
Unité de recherche du site Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie - PTM - EA3430
Langue

en
Volume

85
Numéro

2
Page de début

276
Page de fin

281
Date de première publication

2014
ISSN

1872-8332
Titre de la source (revue, livre…)

Lung Cancer
Résumé

OBJECTIVES: Pulmonary sarcomatoid carcinomas (SC) are highly disseminated types of non-small-cell lung carcinoma. Their prognosis is poor. New therapeutic targets are needed to improve disease management. MATERIALS AND METHODS: From 1995 to 2013,
Show moreOBJECTIVES: Pulmonary sarcomatoid carcinomas (SC) are highly disseminated types of non-small-cell lung carcinoma. Their prognosis is poor. New therapeutic targets are needed to improve disease management. MATERIALS AND METHODS: From 1995 to 2013, clinical and survival data from all consecutive patients with surgically treated SC were collected. Pathological and biomarker analyses were performed: TTF1, P63, c-MET and ALK expression (immunohistochemistry), PAS staining, ALK rearrangement (FISH), and EGFR, KRAS, HER2, BRAF, PIK3CA, and MET genes mutations (PCR). RESULTS: Seventy-seven patients were included. Median age was 61 years (53-69). Histological subtypes were pleomorphic carcinoma (78%), carcinosarcoma (12%), and giant-cell and/or spindle-cell carcinoma (10%). Blood vessel invasion (BVI) was present in 90% of cases. Morphology and immunohistochemistry were indicative of an adenocarcinoma, squamous, and adenosquamous origin in 41.5%, 17% and 11.5%, respectively, 30% remained not-otherwise-specified. KRAS, PIK3CA, EGFR, and MET mutations were found in 31%, 8%, 3%, and 3%, respectively. No tumors had HER2 or BRAF mutations, or ALK rearrangement, whereas 34% had a c-MET positive score. Five-year overall survival (OS) was 29% for the whole population. At multivariate analysis, tumor size <50mm (HR=1.96 [1.04-3.73], p=0.011), no lymph-node metastasis (HR=3.25 [1.68-6.31], p<0.0001), no parietal pleural invasion (HR=1.16 [1.06-1.28], p=0.002), no BVI (HR=1.22 [1.06-1.40], p=0.005), and no squamous component (HR=3.17 [1.48-6.79], p=0.01) were associated with longer OS. Biomarkers did not influence OS. CONCLUSION: Dedifferentiation in NSCLC could lead to SC and an epithelial subtype component could influence outcome. BVI was present in almost all SCs and was an independent factor of poor prognosis.
Show less
DOI 10.1016/j.lungcan.2014.06.004
Éditeur

Elsevier
Type de publication

journal article
Type de publication

ACL
Fonction

ctb
aut
URL https://univoak.eu/islandora/object/islandora:53944